

**Amendments to the Claims**

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1. (Currently amended) A method of promoting viability of a transplant cell population comprising contacting the transplant cell population with an effective amount of a compound selected from the group consisting of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein cells of the transplant cell population are dopamine neurons or precursors thereof.
2. (Currently amended) The method of claim 1 wherein cells of the transplant cell population are differentiated dopamine neurons ~~cells~~.
3. (Currently amended) The method of claim 1 wherein cells of the transplant cell population are precursor cells of dopamine neurons selected from the group consisting of pluripotent stem cell, embryonic stem cells, adult stem cells and combinations thereof.
4. (Original) The method of claim 1 wherein the contacting occurs *in vitro*.
5. (Withdrawn) The method of claim 1 wherein the contacting occurs *in vivo*.
6. (Withdrawn) The method of claim 5 wherein the contacting occurs in a donor of the transplant cell population.

7. (Previously presented) The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population with the compound *in vitro* prior to transplanting the transplant cell population in a subject.
8. (Original) The method of claim 7 wherein the subject is a human.
9. (Withdrawn/currently amended) The method of claim [[7]] 72 further comprising treating the subject with the compound.
10. (Withdrawn) The method of claim 9 wherein treating the subject with the compound comprises administering the compound to the subject prior to transplanting the transplant cell population in the subject.
11. (Withdrawn) The method of claim 10 wherein treating the subject with the compound further comprises administering the compound to the subject after transplanting the transplant cell population in the subject.
12. (Withdrawn) The method of claim 9 wherein treating the subject with the compound comprises administering the compound to the subject after transplanting the transplant cell population in the subject.
13. (Withdrawn) The method of claim 9 wherein treating the subject comprises treating the subject parenterally with the compound.
14. (Withdrawn) The method of claim 9 wherein treating the subject comprises treating the subject orally with the compound.

15. (Original) The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
16. (Original) The method of claim 1 wherein the cells of the transplant cell population comprise autologous cells, heterologous cells, or xenologous cells.
17. (Original) The method of claim 1 wherein the cells of the transplant cell population comprises at least a portion of autologous tissue, heterologous tissue, or xenologous tissue.
- 18-22. (Canceled)
23. (Withdrawn/currently amended) A method of promoting the viability of a cell transplant population in the treatment of a subject having Parkinson's disease, the method comprising:  
contacting the transplant cell population *in vitro* with an effective amount of a compound selected from the group consisting of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein cells of the transplant cell population are dopamine neurons or precursors thereof to promote viability of the transplant cell population; and  
transplanting the transplant cell population into the subject.
24. (Withdrawn) The method of claim 23 wherein the ursodeoxycholic acid analog includes a conjugated derivative.
25. (Withdrawn) The method of claim 24 wherein the conjugated derivative is tauroursodeoxycholic acid.
26. (Withdrawn) The method of claim 23 wherein the subject is a human.

**Amendment and Response**

Serial No.: 10/549,867

Confirmation No.: 4764

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

---

Page 5 of 16

27. (Withdrawn/currently amended) The method of claim 23 wherein the cells of the transplant cell population are differentiated dopamine neurons ~~cells~~.

28. (Withdrawn/currently amended) The method of claim 23 wherein the cells of the transplant cell population are precursor cells of dopamine neurons selected from the group consisting of pluripotent stem cell, embryonic stem cells, adult stem cells and combinations thereof.

29. (Withdrawn/currently amended) The method of claim ~~[[27]]~~ 23 wherein the dopamine neurons are human embryonic dopamine neurons ~~cells are neuronal cells~~.

30. (Withdrawn/currently amended) The method of claim ~~[[28]]~~ 23 wherein the cells of the transplant cell population are transplanted onto the brain ~~neuronal cells~~.

31-32. (Canceled)

33. (Withdrawn) The method of claim 23 further comprising treating the subject with the compound.

34. (Withdrawn) The method of claim 33 wherein treating the subject with the compound comprises administering the compound to the subject prior to transplanting the cells in the subject.

35. (Withdrawn) The method of claim 34 wherein treating the subject with the compound further comprises administering the compound to the subject after transplanting the cells in the subject.

**Amendment and Response**

Serial No.: 10/549,867

Confirmation No.: 4764

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

---

Page 6 of 16

36. (Withdrawn) The method of claim 33 wherein treating the subject with the compound comprises administering the compound to the subject after transplanting the cells in the subject.
37. (Withdrawn) The method of claim 33 wherein treating the subject comprises treating the subject parenterally with the compound.
38. (Withdrawn) The method of claim 33 wherein treating the subject comprises treating the subject orally with the compound.
39. (Withdrawn) The method of claim 23 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
40. (Withdrawn) The method of claim 23 wherein the cells comprise autologous cells, heterologous cells, or xenologous cells.
41. (Withdrawn/currently amended) The method of claim 23 wherein the cells of the transplant cell population are embryonic ventral mesencephalic ~~comprise neuronal~~ cells.
- 42-43. (Canceled)
44. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein the ursodeoxycholic acid comprises tauroursodeoxycholic acid.
45. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein the donor of the transplant cell population is living.

**Amendment and Response**

Serial No.: 10/549,867

Confirmation No.: 4764

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

---

Page 7 of 16

46. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein treating the donor comprises treating the donor with the compound before removal of the transplant cell population from the donor.

47. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein treating the donor comprises treating the donor with the compound during removal of the transplant cell population from the donor.

48-50. (Cancel)

51. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein treating the donor comprises treating the donor parenterally with the compound.

52. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein treating the donor comprises treating the donor orally with the compound.

53. (Withdrawn/currently amended) The method of claim [[42]] 6 wherein treating the donor with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.

54-65. (Cancel)

66. (Previously presented) The method of claim 1 wherein the ursodeoxycholic acid analog includes a conjugated derivative.

67. (Previously presented) The method of claim 66 wherein the conjugated derivative is tauroursodeoxycholic acid.

**Amendment and Response**

Serial No.: 10/549,867

Confirmation No.: 4764

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

---

Page 8 of 16

68. (Currently amended) The method of claim 1 wherein the ~~cells~~ dopamine neurons are ~~neuronal cells~~ human embryonic dopamine neurons.
69. (Withdrawn/currently amended) The method of claim [[68]] 4, further comprising transplanting the cell population ~~wherein the cells are transplanted~~ into a subject with Parkinson's disease.
70. (Withdrawn/currently amended) The method of claim [[68]] 69 wherein the survival of dopamine neurons in the transplanted ~~neuronal~~ cell population is enhanced.
71. (Withdrawn/currently amended) The method of claim [[68]] 69 wherein apoptosis of dopamine neurons in the transplanted cell population is reduced.
72. (Withdrawn/currently amended) The method of claim [[1]] 4 further comprising transplanting the transplant cell population into a subject.
73. (Withdrawn/previously presented) The method of claim 72 further comprising administering an immunosuppressive pharmaceutical to the subject.
74. (Withdrawn/previously presented) The method of claim 23 further comprising administering an immunosuppressive pharmaceutical to the subject.
75. (New) The method of claim 23 wherein the cells of the transplant cell population are transplanted onto the brain.
76. (New) The method of claim 72 wherein the cells of the transplant cell population are transplanted onto the brain.

**Amendment and Response**

Serial No.: 10/549,867

Confirmation No.: 4764

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

---

Page 9 of 16

77. (New) The method of claim 4 wherein the cells of the transplant cell population are embryonic ventral mesencephalic cells.
78. (New) The method of claim 1 wherein the cells of the transplant cell population are embryonic ventral mesencephalic cells.
79. (New) The method of claim 1, further comprising transplanting the cell population into a subject with Parkinson's disease.
80. (New) The method of claim 1 further comprising transplanting the transplant cell population into a subject.